Ann: June 2018 Appendix 4C - Quarterly, page-44

Apart from its two lead products PTX-200 and PTX-100 they can also have some potential success with its licensed Co-X-Gene platform technology. Any payment i suspect will be larger than its market cap imo.

Prescient has licensed access to its Co-X-Gene™ platform technology to French biotechnology company Transgene (https://www.transgene.fr) for use in two immunotherapeutic products TG4001 and TG4010

https://www.transgene.fr/wp-content/uploads/2018/01/20180116-PR-FPI-TG4010-1L-EN.pdf

First Patient Dosed in a Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Lung Cancer (NSCLC)

Clinical Trial in Collaboration with Bristol-Myers Squibb

  Trial Will Enroll Patients whose Tumors Express Low or Undetectable Levels of PD-L1

First results expected in H2 2018